Through the temporal analysis of occurrence of aberrations, some driver mutations specifically associated with steps in the progression of prostate cancer are identified: thus, mutations in SPOP and ETS fusions occur early in cancer development and are exclusively clonal; loss of CHD1 and BRCA2 appear to be early events in development of ETS fusion-negative prostate cancers [65]. The gene discussed is BRCA2; the disease is prostate carcinoma.